EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study

Jalpa Devi, Anthony Xu, Molly Stone, Anish Patel, Abdul Khan, Nikhil Reddy, Jeremy Klein, Navreet Chowla, Caroline Benson, Bryan Christopher Luu, Katherine Huang, Fnu Jaiprada und 10 weitere

Clinical Gastroenterology and Hepatology · 2025-11 · 23 (12) · 2281-2291.e4

DOI: 10.1016/j.cgh.2025.01.012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-11. Verfasst von Jalpa Devi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Saint Louis Zoo, Crohn's and Colitis Foundation of America, University of Chicago Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor, in patients with Crohn's disease (CD). METHODS: A retrospective analysis was conducted across 9 centers in the United States, focusing on adults with CD treated with UPA, 45 mg, as induction therapy for active luminal disease. The coprimary end points were clinical remission at 12 weeks (Harvey Bradshaw Index ≤4 or absence of symptoms on physician's global assessment) and endoscopic remission at 6 months (Simplified Endoscopic Mucosal Assessment for Crohn's Disease score of 0-1 or absence of ulcers). Secondary outcomes included clinical, radiographic, and histologic outcomes, and adverse events. RESULTS: The study included 334 patients with CD (median age, 34 years; disease duration, 12 years; 44.6% female). Clinical remission was achieved in 52.1% at 12 weeks and 55.9% at 6 months. Endoscopic remission at 6 months was observed in 42.7% of patients. Advanced therapy-naive patients achieved a higher proportion of clinical remission at 12 weeks (58.6%) and 6 months (97.7%) compared with patients with 1 prior advanced therapy (53.3% and 66.7%) and 2 or more prior advanced therapy exposures (50.2% and 40.5%), respectively. Body mass index and longer disease duration was associated with lower odds of clinical remission at 12 weeks. Adverse events were reported in 13.5% and UPA discontinued in 19.1%. CONCLUSIONS: UPA was effective at inducing clinical and endoscopic remission in a real-world group of patients with CD, even with prior exposure to multiple prior advanced therapies. No new safety concerns were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDrug-Related Side Effects and Adverse ReactionsRemission InductionRetrospective StudiesTreatment OutcomeUnited States

Stichwörter der Autor:innen

Crohn's DiseaseJanus Kinase InhibitorReal-World EffectivenessUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingJanus Kinase Inhibitorsupadacitinib

Autor:innen und Institutionen

  • Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri.
  • Division of Gastroenterology, Baylor College of Medicine, Houston, Texas.
  • Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan.
  • Division of Gastroenterology, Brooke Army Medical Center, San Antonio, Texas.
  • Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California.
  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.

Förderung

  • Saint Louis Zoo
  • Crohn's and Colitis Foundation of America
  • University of Chicago Medicine
  • Brooke Army Medical Center
  • School of Medicine, Washington University in St. Louis
  • American College of Gastroenterology

Zitieren

APA

Devi, J., Xu, A., Stone, M., Patel, A., Khan, A., Reddy, N., Klein, J., Chowla, N., Benson, C., Luu, B. C., Huang, K., Jaiprada, F., Fenster, M., Ungaro, R., Pekow, J., Johnson, A. M., Yarur, A. J., Shukla, R., Huecker, J., …, & Deepak, P. (2025). Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study. Clinical Gastroenterology and Hepatology, 23(12), 2281-2291.e4. https://doi.org/10.1016/j.cgh.2025.01.012

Vancouver

Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, et al. Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study. Clinical Gastroenterology and Hepatology. 2025;23(12):2281-2291.e4. doi:10.1016/j.cgh.2025.01.012

BibTeX
@article{Devi2025,
  author = {Devi, Jalpa and Xu, Anthony and Stone, Molly and Patel, Anish and Khan, Abdul and Reddy, Nikhil and Klein, Jeremy and Chowla, Navreet and Benson, Caroline and Luu, Bryan Christopher and Huang, Katherine and Jaiprada, Fnu and Fenster, Marc and Ungaro, Ryan and Pekow, Joel and Johnson, Amanda M and Yarur, Andres J and Shukla, Richa and Huecker, Julia and Bishu, Shrinivas and REBOOT IBD Consortium, REBOOT IBD Consortium and Deepak, Parakkal},
  title = {Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {12},
  pages = {2281--2291.e4},
  doi = {10.1016/j.cgh.2025.01.012}
}
Kostenlos starten →